ReviewAdvances in radiation oncology
Toxicity of radiation and immunotherapy combinations.
Review in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Simultaneous integrated dose reduction intensity-modulated radiotherapy effectively reduces cardiac toxicity in limited-stage small cell lung cancer.Cancer biology & medicine · 2023Pooled it
- Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.European urology oncology · 2022Trial
- Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.Cancer immunology research · 2019Trial
- Harnessing the abscopal effect: mechanistic insights and therapeutic strategies for systemic cancer immunotherapy.Frontiers in immunology · 2026Review
- Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.Mathematical biosciences · 2025Article
- Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience.Advances in radiation oncology · 2024Article
- A review on lymphocyte radiosensitivity and its impact on radiotherapy.Frontiers in oncology · 2023Review
- Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.European urology oncology · 2022Article
- Review
- Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience.Current oncology (Toronto, Ont.) · 2022Article
- Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer.Frontiers in oncology · 2021Article
- Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.Journal for immunotherapy of cancer · 2020Article
- Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.Journal for immunotherapy of cancer · 2019Article
- MicroRNA-21 is Required for Hematopoietic Cell Viability After Radiation Exposure.International journal of radiation oncology, biology, physics · 2019Article
- Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer.Frontiers in oncology · 2019Article
- Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?International journal of molecular sciences · 2018Review
- Efficacy of current therapeutic strategies for immune checkpoint inhibitor-related esophagitis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough immunotherapy is a rapidly emerging modality for cancer care, there have been multiple reports of fatal toxicities. There have also been cases of treatment-related deaths with combined non-immunotherapeutic biologic compounds with radiation therapy. Thus, provision of summative information appraising the safety of combinatorial immunotherapy and radiation therapy (iRT) is imperative. Because this has not been well characterized, this review summarizes the available evidence to date. METHODS AND MATERIALS: Owing to the heterogeneity and relatively low quantity of published reports, this review was conducted in a narrative rather than systematic format.
resultsThe results of combined iRT, both concurrent and sequential, are discussed for oncologic therapy of the brain, lung, liver, and prostate. Most evidence is from small samples and shorter follow-up but does consist of multiple prospective publications. Most data exist for ipilimumab, with programmed cell death -1 inhibitors emerging in more recent years. With 2 large phase 3 trials as exceptions, there were no instances of iRT-related deaths across all discussed studies. Altogether, grade 3 to 4 toxicities were relatively low in frequency; of the studies that compared iRT with an "immunotherapy only" or "RT only" cohort, none documented a clear increase in high-grade adverse events with combined-modality management.
conclusionsDespite the low quantity of data, combined iRT offers encouraging safety profiles. There is no evidence that iRT produces an overt increase in high-grade toxicities. Further data, especially on concurrent iRT, are anticipated from numerous iRT trials that are currently ongoing worldwide.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.